Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Loud JT, Gierach GL, Veenstra TD et al (2014) Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. Breast Cancer Res Treat 143:517–529PubMedCrossRef
2.
Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD, Ziegler RG (2007) Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem 79:7813–7821PubMedCrossRef
3.
Metadata
Title
Concerns about methods for determination of estrogens in body fluids
Authors
Robert T. Chatterton
Miguel Muzzio
Peter H. Gann
Publication date
01-12-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3177-2

Other articles of this Issue 3/2014

Breast Cancer Research and Treatment 3/2014 Go to the issue

Epidemiology

Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer

Epidemiology

Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast

Clinical Trial

Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial

Review

The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis

Epidemiology

Degree of urbanization and mammographic density in Dutch breast cancer screening participants: results from the EPIC-NL cohort

Clinical trial

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits